Concepedia

Anacetrapib as lipid-modifying therapy in patients with heterozygous familial hypercholesterolaemia (REALIZE): a randomised, double-blind, placebo-controlled, phase 3 study

John J.P. Kastelein, Joost Besseling, Sukrut Shah, Jean Bergeron, Gisle Langslet, G. Kees Hovingh, Naab Al‐Saady, Michiel Koeijvoets, John Hunter, Amy O. Johnson‐Levonas,

The Lancet · 2015 · 100 citations · 22 references

DOI

Concepts

References

22

Estimation of the Concentration of Low-Density Lipoprotein Cholesterol in Plasma, Without Use of the Preparative Ultracentrifuge

William T. Friedewald, Robert I. Levy, Donald S. Fredrickson · Clinical Chemistry · 1972 · 32.5K citations

, , +14

Effects of Torcetrapib in Patients at High Risk for Coronary Events

Philip J. Barter, Mark J. Caulfield, Mats Eriksson et al. · New England Journal of Medicine · 2007 · 3.1K citations · Full text

, , +14

Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy

New England Journal of Medicine · 2011 · 2.9K citations · Full text

, , +9

Effects of Dalcetrapib in Patients with a Recent Acute Coronary Syndrome

Gregory G. Schwartz, Anders Olsson, Markus Abt et al. · New England Journal of Medicine · 2012 · 2K citations · Full text

, , +17

Effects of Extended-Release Niacin with Laropiprant in High-Risk Patients

New England Journal of Medicine · 2014 · 1.7K citations · Full text

, , +17